Header Logo

MICHAEL JAMES OVERMAN

TitleAssociate Professor
InstitutionMD Anderson
DepartmentGI Medical Oncology
Address1400 Holcombe Blvd
Houston TX 77030-4008
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Schoenfeld JD, Azad NS, Gross J, Chen L, Overman MJ, Kao K, Jackson LF, Brunnquell D, Bu X, Coppola C, Guan P, Lee J, Sims D, Fuchs R, Weirather JL, Pfaff KL, Gunasti L, Ranasinghe S, Hamilton SR, Wang V, O'Dwyer PJ, Wu CJ, Rodig SJ, Patton DR, Harris L. Next generation sequencing-based MSI scoring predict benefit in mismatch repair deficient tumors treated with nivolumab: follow-up on NCI-MATCH arm Z1D. Clin Cancer Res. 2024 Dec 13. PMID: 39670863.
      Citations:    
    2. Ecker BL, Seier K, Eckhoff AM, Tortorello GN, Allen PJ, Balachandran VP, Blackburn N, D'Angelica MI, DeMatteo RP, Blazer DG, Drebin JA, Fisher WE, Fortuna D, Gill AJ, Gingras MC, Kingham TP, Lee MK, Lidsky ME, Nussbaum DP, Overman MJ, Samra JS, Shen R, Sigel CS, Soares KC, Vollmer CM, Wei AC, Zani S, Roses RE, Gonen M, Jarnagin WR. Genome-Derived Ampullary Adenocarcinoma Classifier and Postresection Prognostication. JAMA Surg. 2024 Dec 01; 159(12):1365-1373. PMID: 39259526; PMCID: PMC11391358.
      Citations:    Fields:    
    3. Holla VR, Kahle MP, Kim SH, Ronaghy A, Yang RK, Patel KP, Routbort MJ, Overman MJ, Dumbrava EE, Mills Shaw KR, Karp DD, Meric-Bernstam F. Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types. JCO Precis Oncol. 2024 Nov; 8:e2400419. PMID: 39576951.
      Citations:    Fields:    Translation:HumansCells
    4. Yousef M, Yousef A, Chowdhury S, Fanaeian MM, Knafl M, Peterson J, Zeineddine M, Alfaro K, Zeineddine F, Goldstein D, Hornstein N, Dasari A, Huey R, Johnson B, Higbie V, Bent A, Kee B, Lee M, Morelli MP, Morris VK, Halperin D, Overman MJ, Parseghian C, Vilar E, Wolff R, Raghav KP, White MG, Uppal A, Sun R, Wang W, Kopetz S, Willis J, Shen JP. Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival. JAMA Oncol. 2024 Nov 01; 10(11):1519-1529. PMID: 39264607; PMCID: PMC11393757.
      Citations:    Fields:    Translation:Humans
    5. Coveler AL, Reilley MJ, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvise M, Nagrial A, Uboha NV, Frentzas S, Overman M, Noonan A, Messersmith WA, Pavlakis N, Mettu NB, Bisha I, Wang Y, Smith P, Murtomaki E, Bielska AA, Bragulat V, Cooper ZA, Kumar R, Spigel DR, Coveler AL, Reilley MJ, Zalupski M, Macarulla T, Fountzilas C, Ponz-Sarvis? M, Nagrial A, Uboha NV, Frentzas S, Overman M, Noonan A, Messersmith WA, Pavlakis N, Mettu NB, Bisha I, Wang Y, Smith P, Murtomaki E, Bielska AA, Bragulat V, Cooper ZA, Kumar R, Spigel DR. A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2024 Oct 15; 30(20):4609-4617. PMID: 39106081; PMCID: PMC11474165.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. Margalit O, Stemmer A, Chapin WJ, Shacham-Shmueli E, Kopetz S, Andre T, Overman MJ, Pietrantonio F, Boursi B. Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients. Eur J Cancer. 2024 Nov; 212:114336. PMID: 39316932.
      Citations:    Fields:    Translation:HumansCells
    7. Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR, Tang C, Msaouel P, Ludmir EB, Beck EJ, Sherry AD, Florez MA, Kouzy R, Abi Jaoude J, Lin TA, Miller AM, Passy AH, Kupferman GS, Patel RR, Chino F, Higbie VS, Parseghian CM, Overman MJ, Minsky BD, Thomas CR, Tang C, Msaouel P, Ludmir EB. Secondary Endpoint Utilization and Publication Rate among Phase III Oncology Trials. Cancer Res Commun. 2024 Aug 01; 4(8):2183-2188. PMID: 39099199; PMCID: PMC11333994.
      Citations:    Fields:    Translation:Humans
    8. Yousef M, Hurd MW, Yousef A, Ludmir EB, Pillai AB, Peterson J, Koay EJ, Albarouki S, Tzeng CW, Snyder R, Katz MHG, Wang H, Overman MJ, Maitra A, Pant S, Smaglo BG, Wolff RA, Yao J, Shen JP, Zhao D. Clinical and molecular characteristics of patients with brain metastasis secondary to pancreatic ductal adenocarcinoma. Oncologist. 2024 Jul 16. PMID: 39014543.
      Citations:    Fields:    
    9. Benson AB, Venook AP, Adam M, Chang G, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Haste P, Hecht JR, Hoffe S, Hunt S, Hussan H, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber JM, Sofocleous CT, Tavakkoli A, Willett CG, Wu C, Gurski LA, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 06; 22(2 D). PMID: 38862008.
      Citations: 10     Fields:    Translation:Humans
    10. Overman MJ, Gelsomino F, Aglietta M, Wong M, Limon Miron ML, Leonard G, Garc?a-Alfonso P, Hill AG, Cubillo Gracian A, Van Cutsem E, El-Rayes B, McCraith SM, He B, Lei M, Lonardi S. Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Immunother Cancer. 2024 May 31; 12(5). PMID: 38821718; PMCID: PMC11149130.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    11. Hornstein NJ, Zeineddine MA, Gunes BB, Pellatt AJ, Knafl M, Zhu H, Willett AF, Yousef A, Liu S, Sun R, Futreal A, Woodman SE, Taggart MW, Overman MJ, Halperin DM, Raghav KP, Shen JP. Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Res Commun. 2024 May 29; 4(5):1363-1368. PMID: 38709066; PMCID: PMC11135244.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    12. Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, Andr? T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul; 35(7):643-655. PMID: 38777726.
      Citations: 3     Fields:    Translation:HumansCells
    13. Maddalena G, Zeineddine FA, Rivero-Hinojosa S, Aushev VN, Chowdhury S, Zeineddine MA, Yousef AM, Yap TA, EINaggar AC, Liu MC, White M, Overman MJ, Kopetz S, Shen JP. Defining the subset of mutations in polymerase epsilon (POLE) associated with loss-of-proofreading (LOP) functionality. Ann Oncol. 2024 Jul; 35(7):678-680. PMID: 38734075.
      Citations:    Fields:    Translation:Humans
    14. Chang E, Wong FCL, Chasen BA, Erwin WD, Das P, Holliday EB, Koong AC, Ludmir EB, Minsky BD, Noticewala SS, Smith GL, Taniguchi CM, Rodriguez MJ, Beddar S, Martin-Paulpeter RM, Niedzielski JS, Sawakuchi GO, Schueler E, Perles LA, Xiao L, Szklaruk J, Park PC, Dasari AN, Kaseb AO, Kee BK, Lee SS, Overman MJ, Willis JA, Wolff RA, Tzeng CD, Vauthey JN, Koay EJ. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3). PMID: 38730548; PMCID: PMC11164414.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    15. Johnson B, Morris V, Wang X, Dasari A, Raghav K, Shen JP, Lee MS, Huey R, Parseghian C, Willis J, Wolff R, Drusbosky LM, Overman MJ, Kopetz S. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling. Cancers (Basel). 2024 Feb 09; 16(4). PMID: 38398128; PMCID: PMC10886949.
      Citations:    
    16. Yousef A, Yousef M, Zeineddine MA, More A, Fanaeian M, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine FA, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally CP, Kee B, Kopetz S, Goldstein D, Strach M, Williamson A, Aziz O, Barriuso J, Uppal A, White MG, Helmink B, Fournier KF, Raghav KP, Taggart MW, Overman MJ, Shen JP. Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma. JAMA Netw Open. 2024 02 05; 7(2):e240260. PMID: 38416491; PMCID: PMC10902735.
      Citations: 4     Fields:    Translation:Humans
    17. Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2024 Feb 03; 8(1):27. PMID: 38310130; PMCID: PMC10838312.
      Citations: 8     
    18. Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2). PMID: 38309721; PMCID: PMC10840042.
      Citations: 4     Fields:    Translation:HumansCells
    19. Cohen R, Raeisi M, Chibaudel B, Yoshino T, Shi Q, Zalcberg JR, Adams R, Cremolini C, Grothey A, Mayer RJ, Van Cutsem E, Tabernero J, Bando H, Misumi T, Overman MJ, Andr? T, de Gramont A. Efficacy of immune checkpoint inhibitors for metastatic colorectal cancer with microsatellite instability in second or latter line using synthetic control arms: A non-randomised evaluation. Eur J Cancer. 2024 Mar; 199:113537. PMID: 38241818.
      Citations: 2     Fields:    Translation:Humans
    20. Stemmer A, Margalit O, Serpas V, Strauss G, Thomas J, Shah P, Tau N, Levanon K, Shacham-Shmueli E, Kopetz S, Overman M, Boursi B. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers. Eur J Cancer. 2024 Feb; 198:113495. PMID: 38157568.
      Citations: 1     Fields:    Translation:HumansCells
    21. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. Taxane-Based Chemotherapy Is Effective in Metastatic Appendiceal Adenocarcinoma. Oncologist. 2023 Dec 11; 28(12):e1303-e1305. PMID: 37738316; PMCID: PMC10712908.
      Citations:    Fields:    Translation:Humans
    22. Simmons K, Thomas JV, Ludford K, Willis JA, Higbie VS, Raghav KPS, Johnson B, Dasari A, Kee BK, Parseghian CM, Lee MS, Le PH, Morelli MP, Shen JP, Bent A, Vilar E, Wolff RA, Kopetz S, Overman MJ, Morris VK. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Res Commun. 2023 12 11; 3(12):2510-2517. PMID: 38085001; PMCID: PMC10712284.
      Citations: 1     Fields:    Translation:Humans
    23. Bhutiani N, Grotz TE, Concors SJ, White MG, Helmink BA, Raghav KP, Taggart MW, Beaty KA, Royal RE, Overman MJ, Matamoros A, Scally CP, Rafeeq S, Mansfield PF, Fournier KF. Repeat Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Mucinous Appendiceal Adenocarcinoma: A Viable Treatment Strategy with Demonstrable Benefit. Ann Surg Oncol. 2024 Jan; 31(1):614-621. PMID: 37872456; PMCID: PMC10695875.
      Citations: 1     Fields:    Translation:Humans
    24. Fox DA, Bhamidipati D, Konishi T, Kaur H, You N, Raghav KPS, Ge PS, Messick C, Johnson B, Morris VK, Thomas JV, Shah P, Bednarski BK, Kopetz S, Chang GJ, Ludford K, Higbie VS, Overman MJ. Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356. PMID: 37827065.
      Citations:    Fields:    Translation:HumansCells
    25. Yousef A, Yousef M, Zeineddine M, More A, Chowdhury S, Knafl M, Edelkamp P, Ito I, Gu Y, Pattalachinti V, Naini ZA, Zeineddine F, Peterson J, Alfaro K, Foo WC, Jin J, Bhutiani N, Higbie V, Scally C, Kee B, Kopetz S, Goldstein D, Uppal A, White MG, Helmink B, Fournier K, Raghav K, Taggart M, Overman MJ, Shen JP. The Clinical Significance of CEA, CA19-9, and CA125 in Management of Appendiceal Adenocarcinoma. medRxiv. 2023 Sep 11. PMID: 37745596; PMCID: PMC10516068.
      Citations:    
    26. Colle R, Lonardi S, Cachanado M, Overman MJ, Elez E, Fakih M, Corti F, Jayachandran P, Svrcek M, Dardenne A, Cervantes B, Duval A, Cohen R, Pietrantonio F, Andr? T. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors. Oncologist. 2023 09 07; 28(9):771-779. PMID: 37023721; PMCID: PMC10485382.
      Citations: 2     Fields:    Translation:HumansCells
    27. Napolitano S, Parikh AR, Henry J, Parseghian CM, Willis J, Raghav KP, Morris VK, Johnson B, Kee BK, Dasari AN, Overman MJ, Luthra R, Drusbosky LM, Corcoran RB, Kopetz S, Sun R. Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precis Oncol. 2023 09; 7:e2300228. PMID: 37824798.
      Citations:    Fields:    Translation:Humans
    28. Yousef A, Yousef M, Chowdhury S, Abdilleh K, Knafl M, Edelkamp P, Alfaro-Munoz K, Chacko R, Peterson J, Smaglo BG, Wolff RA, Pant S, Lee MS, Willis J, Overman M, Doss S, Matrisian L, Hurd MW, Snyder R, Katz MHG, Wang H, Maitra A, Shen JP, Zhao D. Impact of KRAS Mutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma. Res Sq. 2023 Aug 10. PMID: 37609177; PMCID: PMC10441514.
      Citations:    
    29. Topham JT, Huey RW, Shah AT, Reddi HV, Dasari P, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst. 2023 08 08; 115(8):994-997. PMID: 37202363; PMCID: PMC10407690.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    30. Zhang Y, Wang H, Overman M, Katz MH, Wang H. Prognostic significance of trophoblastic cell surface antigen 2 expression and pathologic parameters in patients with ampullary adenocarcinoma. Hum Pathol. 2023 09; 139:117-125. PMID: 37516386.
      Citations:    Fields:    Translation:Humans
    31. Dansby J, More A, Zeineddine M, Yousef A, Bent A, Dayyani F, Wolff R, Overman M, Shen JP. Taxane-based Chemotherapy is Effective in Metastatic Appendiceal Adenocarcinoma. medRxiv. 2023 Jul 13. PMID: 37502847; PMCID: PMC10370227.
      Citations:    
    32. Janczewski LM, Browner AE, Cotler JH, Nelson H, Kakar S, Carr NJ, Hanna NN, Holowatyj AN, Goldberg RM, Washington MK, Asare EA, Overman MJ, American Joint Committee on Cancer Expert Panel on Cancers for the Lower Gastrointestinal Appendix D. Survival outcomes used to validate version 9 of the American Joint Committee on Cancer staging system for appendiceal cancer. CA Cancer J Clin. 2023 Nov-Dec; 73(6):590-596. PMID: 37358310.
      Citations: 2     Fields:    
    33. Shen JP, Yousef AM, Zeineddine FA, Zeineddine MA, Tidwell RS, Beaty KA, Scofield LC, Rafeeq S, Hornstein N, Lano E, Eng C, Matamoros A, Foo WC, Uppal A, Scally C, Mansfield P, Taggart M, Raghav KP, Overman MJ, Fournier K. Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161. PMID: 37261831; PMCID: PMC10236240.
      Citations: 4     Fields:    Translation:Humans
    34. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Hecht JR, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung KL, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 06; 21(6):653-677. PMID: 37308125.
      Citations: 6     Fields:    Translation:Humans
    35. Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen L. Publisher Correction: A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep. 2023 May 23; 13(1):8318. PMID: 37221249; PMCID: PMC10205728.
      Citations:    Fields:    
    36. Florez MA, Jaoude JA, Patel RR, Kouzy R, Lin TA, De B, Beck EJ, Taniguchi CM, Minsky BD, Fuller CD, Lee JJ, Kupferman M, Raghav KP, Overman MJ, Thomas CR, Ludmir EB. Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials. JAMA Netw Open. 2023 05 01; 6(5):e2313819. PMID: 37195664; PMCID: PMC10193180.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    37. Bendell J, LoRusso P, Overman M, Noonan AM, Kim DW, Strickler JH, Kim SW, Clarke S, George TJ, Grimison PS, Barve M, Amin M, Desai J, Wise-Draper T, Eck S, Jiang Y, Khan AA, Wu Y, Martin P, Cooper ZA, Elgeioushi N, Mueller N, Kumar R, Patel SP. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors. Cancer Immunol Immunother. 2023 Jul; 72(7):2443-2458. PMID: 37016126; PMCID: PMC10264501.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    38. Erstad DJ, Robinson KA, Beaty K, Rafeeq S, Chiang YJ, Raghav K, Shen JP, Overman MJ, Foo WC, Taggart MW, Mansfield PF, Royal RE, Fournier KF, Scally CP. Prognostic significance of acellular mucin in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for appendiceal neoplasms. Langenbecks Arch Surg. 2023 Feb 28; 408(1):110. PMID: 36853519.
      Citations:    Fields:    Translation:Humans
    39. Offodile AC, Delgado D, Lin YL, Geyen D, Miller CJ, Jain S, Finder JP, Shete S, Fossella FV, Overman MJ, Peterson SK. Integration of Remote Symptom and Biometric Monitoring Into the Care of Adult Patients With Cancer Receiving Chemotherapy-A Decentralized Feasibility Pilot Study. JCO Oncol Pract. 2023 06; 19(6):e811-e821. PMID: 36821818; PMCID: PMC10332844.
      Citations:    Fields:    Translation:Humans
    40. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023 Feb 13; 7(1):16. PMID: 36781990; PMCID: PMC9925745.
      Citations: 4     
    41. Anandappa G, Overman MJ. Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer. Cell Rep Med. 2023 01 17; 4(1):100908. PMID: 36652917; PMCID: PMC9873932.
      Citations:    Fields:    Translation:AnimalsCells
    42. Ludford K, Ho WJ, Thomas JV, Raghav KPS, Murphy MB, Fleming ND, Lee MS, Smaglo BG, You YN, Tillman MM, Kamiya-Matsuoka C, Thirumurthi S, Messick C, Johnson B, Vilar E, Dasari A, Shin S, Hernandez A, Yuan X, Yang H, Foo WC, Qiao W, Maru D, Kopetz S, Overman MJ. Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors. J Clin Oncol. 2023 04 20; 41(12):2181-2190. PMID: 36623241; PMCID: PMC10489404.
      Citations: 15     Fields:    Translation:HumansCellsCTClinical Trials
    43. Vikas P, Messersmith H, Compton C, Sholl L, Broaddus RR, Davis A, Estevez-Diz M, Garje R, Konstantinopoulos PA, Leiser A, Mills AM, Norquist B, Overman MJ, Sohal D, Turkington RC, Johnson T. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline. J Clin Oncol. 2023 04 01; 41(10):1943-1948. PMID: 36603179.
      Citations: 3     Fields:    Translation:HumansCells
    44. Nasca V, Barretta F, Corti F, Lonardi S, Niger M, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Cremolini C, Ros J, Ambrosini M, Mazzoli G, Intini R, Overman MJ, Miceli R, Pietrantonio F. Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. J Immunother Cancer. 2023 01; 11(1). PMID: 36593068; PMCID: PMC9809233.
      Citations:    Fields:    Translation:Humans
    45. Newhook TE, Vreeland TJ, Griffin JF, Tidwell RSS, Prakash LR, Koay EJ, Ludmir EB, Smaglo BG, Pant S, Overman M, Wolff RA, Ikoma N, Maxwell J, Kim MP, Lee JE, Katz MHG, Tzeng CD. Prognosis Associated With CA19-9 Response Dynamics and Normalization During Neoadjuvant Therapy in Resected Pancreatic Adenocarcinoma. Ann Surg. 2023 03 01; 277(3):484-490. PMID: 36649067.
      Citations: 5     Fields:    Translation:Humans
    46. Lopez G, Eng C, Overman M, Ramirez D, Liu W, Beinhorn C, Sumler P, Prinsloo S, Li Y, Chen M, Bruera E, Cohen L. A randomized pilot study of oncology massage to treat chemotherapy-induced peripheral neuropathy. Sci Rep. 2022 11 08; 12(1):19023. PMID: 36348045; PMCID: PMC9643426.
      Citations: 1     Fields:    Translation:Humans
    47. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist. 2022 11 03; 27(11):952-957. PMID: 35946836; PMCID: PMC9632313.
      Citations:    
    48. Davis JS, Chavez JC, Kok M, San Miguel Y, Lee HY, Henderson H, Overman MJ, Morris V, Kee B, Fogelman D, Advani SM, Johnson B, Parseghian C, Shen JP, Dasari A, Shaw KR, Vilar E, Raghav KP, Shureiqi I, Wolff RA, Meric-Bernstam F, Maru D, Menter DG, Kopetz S, Chang S. Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer. JAMA Netw Open. 2022 10 03; 5(10):e2236357. PMID: 36239938; PMCID: PMC9568800.
      Citations:    Fields:    Translation:Humans
    49. Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Jeck W, Johung KL, Kirilcuk N, Krishnamurthi S, Maratt JK, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stotsky-Himelfarb E, Tavakkoli A, Willett CG, Gregory K, Gurski L. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 10; 20(10):1139-1167. PMID: 36240850.
      Citations: 41     Fields:    Translation:Humans
    50. Bartley AN, Mills AM, Konnick E, Overman M, Ventura CB, Souter L, Colasacco C, Stadler ZK, Kerr S, Howitt BE, Hampel H, Adams SF, Johnson W, Magi-Galluzzi C, Sepulveda AR, Broaddus RR. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer. Arch Pathol Lab Med. 2022 10 01; 146(10):1194-1210. PMID: 35920830.
      Citations:    
    51. Kanikarla Marie P, Sorokin AV, Bitner LA, Aden R, Lam M, Manyam G, Woods MN, Anderson A, Capasso A, Fowlkes N, Overman MJ, Menter DG, Kopetz S. Autologous humanized mouse models to study combination and single-agent immunotherapy for colorectal cancer patient-derived xenografts. Front Oncol. 2022; 12:994333. PMID: 36212401; PMCID: PMC9532947.
      Citations: 2     
    52. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-? trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun. 2022 09; 2(9):979-986. PMID: 36382087; PMCID: PMC9648419.
      Citations: 4     Translation:Humans
    53. D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection. Sci Transl Med. 2022 08 10; 14(657):eabo7604. PMID: 35947675; PMCID: PMC9844517.
      Citations:    
    54. Hester CA, Perri G, Prakash LR, Maxwell JE, Ikoma N, Kim MP, Tzeng CD, Smaglo B, Wolff R, Javle M, Overman MJ, Lee JE, Katz MHG. Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. J Natl Compr Canc Netw. 2022 08; 20(8):887-897.e3. PMID: 35948035.
      Citations:    
    55. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8). PMID: 36007963; PMCID: PMC9422817.
      Citations:    
    56. Yu K, Mathew A, Abraham F, Amin R, Kono M, Overman M, Zhao D, Khan A, Khan MA, Thomas AS, Wang Y. Immune checkpoint inhibitor-related gastrointestinal toxicity in patients with malignancy involving the luminal gastrointestinal tract and its impact on cancer outcomes. Ann Gastroenterol. 2022 Sep-Oct; 35(5):514-521. PMID: 36061157; PMCID: PMC9399574.
      Citations:    
    57. Koay EJ, Zaid M, Aliru M, Bagereka P, Van Wieren A, Rodriguez MJ, Jacobson G, Wolff RA, Overman M, Varadhachary G, Pant S, Wang H, Tzeng CW, Ikoma N, Kim M, Lee JE, Katz MH, Tamm E, Bhosale P, Taniguchi CM, Holliday EB, Smith GL, Ludmir EB, Minsky BD, Crane CH, Koong AC, Das P, Wang X, Javle M, Krishnan S. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453. PMID: 35863672.
      Citations:    Fields:    
    58. Willis JA, Overman MJ. Inducing Hypermutability to Promote Anti-PD-1 Therapy Response. Cancer Discov. 2022 07 06; 12(7):1612-1614. PMID: 35791694; PMCID: PMC10373529.
      Citations:    Fields:    Translation:HumansCells
    59. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2023 05 01; 277(5):813-820. PMID: 35797554.
      Citations:    Fields:    
    60. Mazzoli G, Lonardi S, Corti F, Elez E, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Ambrosini M, Ros J, Intini R, Cremolini C, Overman MJ, Pietrantonio F, Cohen R, Colle R, Salvatore L, Andr? T. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Eur J Cancer. 2022 09; 172:171-181. PMID: 35777274.
      Citations:    Fields:    
    61. Andr? T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Abdullaev S, Memaj A, Lei M, Dixon M, Kopetz S, Overman MJ. Nivolumab?plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022 10; 33(10):1052-1060. PMID: 35764271.
      Citations:    
    62. Kothari A, White MG, Peacock O, Kaur H, Palmquist SM, You N, Taggart M, Salem U, Overman M, Kopetz S, Chang GJ. Pathological response following neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite instability-high locally advanced, non-metastatic colorectal cancer. Br J Surg. 2022 05 16; 109(6):489-492. PMID: 35576377.
      Citations:    Fields:    Translation:HumansCells
    63. Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, Johnson B, Kopetz S, Morris V, Overman M, Parseghian C, Chang GJ, Lopez-Olivo MA, Kanwal R, Ellis LM, Dasari A. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open. 2022 05 02; 5(5):e2213588. PMID: 35608860; PMCID: PMC9131746.
      Citations:    Fields:    Translation:Humans
    64. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5). PMID: 35618285; PMCID: PMC9125753.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    65. Offodile AC, DiBrito SR, Finder JP, Shete S, Jain S, Delgado DA, Miller CJ, Davidson E, Overman MJ, Peterson SK. Active surveillance of chemotherapy-related symptom burden in ambulatory cancer patients via the implementation of electronic patient-reported outcomes and sensor-enabled vital signs capture: protocol for a decentralised feasibility pilot study. BMJ Open. 2022 04 05; 12(4):e057693. PMID: 35383081; PMCID: PMC8984061.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    66. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol. 2022 Apr; 13(2):647-656. PMID: 35557581; PMCID: PMC9086049.
      Citations:    
    67. Nishioka Y, Chun YS, Overman MJ, Cao HST, Tzeng CD, Mason MC, Kopetz SW, Bauer TW, Vauthey JN, Newhook TE, MD Anderson Cancer Center INTERCEPT Program. Effect of Co-mutation of RAS and TP53 on Postoperative ctDNA Detection and Early Recurrence after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2022 04 01; 234(4):474-483. PMID: 35290266.
      Citations:    Fields:    Translation:Humans
    68. Zhu M, Zhang H, Pedersen KS, Foster NR, Jaszewski BL, Liu X, Hirdler JB, An Z, Bekaii-Saab TS, Halfdanarson TR, Boland PM, Yan Y, Hubbard JH, Ma WW, Yoon HH, Revzin A, Fernandez-Zapico ME, Overman MJ, McWilliams RR, Dong H. Understanding Suboptimal Response to Immune Checkpoint Inhibitors. Adv Biol (Weinh). 2023 04; 7(4):e2101319. PMID: 35343107.
      Citations:    Fields:    
    69. Pandya K, Overman MJ, Gulhati P. Molecular Landscape of Small Bowel Adenocarcinoma. Cancers (Basel). 2022 Mar 02; 14(5). PMID: 35267592; PMCID: PMC8909755.
      Citations: 1     
    70. Overman MJ, Moati E, Zaanan A. Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives. Cancers (Basel). 2022 Feb 23; 14(5). PMID: 35267446; PMCID: PMC8909230.
      Citations:    
    71. Lonardi S, Shitara K, Elez ME, Fakih M, Chao J, Klempner SJ, Emmett M, Jayachandran P, Bergamo F, Mazzoli G, Provenzano L, Ambrosini M, Randon G, Shah AT, Salati M, Fenocchio E, Salvatore L, Chida K, Kawazoe A, Conca V, Curigliano G, Corti F, Cremolini C, Overman M, Pietrantonio F, Fuc? G, Cohen R, Garc?a MD, Colle R, Svrcek M, Andre T. Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers. J Immunother Cancer. 2022 02; 10(2). PMID: 35110358; PMCID: PMC8811606.
      Citations: 2     Fields:    Translation:Humans
    72. Bagley AF, Ludmir EB, Maitra A, Minsky BD, Li Smith G, Das P, Koong AC, Holliday EB, Taniguchi CM, Katz MHG, Tamm EP, Wolff RA, Overman MJ, Patel S, Kim MP, Tzeng CD, Ikoma N, Bhutani MS, Koay EJ. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69. PMID: 35097226; PMCID: PMC8783106.
      Citations: 2     
    73. Randon G, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, Manca P, Bergamo F, Pagani F, Antista M, Angerilli V, Lavacchi D, Boccaccino A, Brich S, Cattaneo L, Fassan M, Pietrantonio F, Lonardi S, Ros Monta?a FJ, Fuc? G. Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer. Eur J Cancer. 2022 01; 161:90-98. PMID: 34933155.
      Citations: 2     Fields:    Translation:Humans
    74. Bhamidipati D, Verma A, Sui D, Maru D, Mathew G, Lang W, Posadas J, Hein J, Kopetz S, Futreal A, Wistuba II, Gupta S, Lee JJ, Overman MJ, Tam AL. An analysis of research biopsy core variability from over 5000 prospectively collected core samples. NPJ Precis Oncol. 2021 Oct 27; 5(1):94. PMID: 34707215; PMCID: PMC8551285.
      Citations:    
    75. Lenz HJ, Van Cutsem E, Luisa Limon M, Wong KYM, Hendlisz A, Aglietta M, Neyns B, Luppi G, Cardin DB, Dragovich T, Shah U, Abdullaev S, Gricar J, Ledeine JM, Overman MJ, Lonardi S, Garc?a-Alfonso P. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022 01 10; 40(2):161-170. PMID: 34637336.
      Citations: 26     Fields:    Translation:HumansCellsCTClinical Trials
    76. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37. PMID: 34794903; PMCID: PMC8917971.
      Citations:    Fields:    Translation:Humans
    77. Rogers JE, Mizrahi JD, Nogueras Gonzalez GM, Surana R, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Raghav K, Pant S. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. J Gastrointest Oncol. 2021 Oct; 12(5):2268-2274. PMID: 34790391; PMCID: PMC8576228.
      Citations:    
    78. Raghav K, Liu S, Overman M, Morani A, Willette A, Fournier K, Varadhachary G. Clinical Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Malignant Peritoneal Mesothelioma. JAMA Netw Open. 2021 08 02; 4(8):e2119934. PMID: 34357397; PMCID: PMC8346939.
      Citations: 1     Fields:    Translation:Humans
    79. Pietrantonio F, Lonardi S, Corti F, Infante G, Elez ME, Fakih M, Jayachandran P, Shah AT, Salati M, Fenocchio E, Salvatore L, Curigliano G, Cremolini C, Ambrosini M, Ros J, Intini R, Nappo F, Damian S, Morano F, Overman M, Miceli R, Fuc? G. Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. J Immunother Cancer. 2021 08; 9(8). PMID: 34429334; PMCID: PMC8386222.
      Citations: 2     Fields:    Translation:Humans
    80. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol. 2021; 11:643815. PMID: 34367949; PMCID: PMC8335590.
      Citations:    
    81. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu SC, Malpica A, Prasad S, Royal RE, Scally CP, Mansfield PF, Wistuba II, Futreal AP, Maru DM, Solis Soto LM, Parra Cuentas ER, Chen H, Villalobos P, Verma A, Mahvash A, Hwu P, Cortazar P, McKenna E, Yun C, Dervin S, Schulze K, Darbonne WC, Morani AC, Kopetz S, Fournier KF, Woodman SE, Yao JC, Varadhachary GR, Halperin DM. Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma. Cancer Discov. 2021 11; 11(11):2738-2747. PMID: 34261675; PMCID: PMC8563380.
      Citations: 8     Fields:    Translation:Humans
    82. Mohindroo C, Hasanov M, Rogers JE, Dong W, Prakash LR, Baydogan S, Mizrahi JD, Overman MJ, Varadhachary GR, Wolff RA, Javle MM, Fogelman DR, Lotze MT, Kim MP, Katz MHG, Pant S, Tzeng CD, McAllister F. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Med. 2021 08; 10(15):5041-5050. PMID: 34250759; PMCID: PMC8335807.
      Citations: 4     Fields:    Translation:Humans
    83. Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, Vanderwalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clin Cancer Res. 2021 08 15; 27(16):4587-4598. PMID: 34117033; PMCID: PMC8364867.
      Citations: 3     Fields:    Translation:Humans
    84. Raghav K, Anand S, Gothwal A, Singh P, Dasari A, Overman MJ, Loree JM. Underreporting of race/ethnicity in COVID-19 research. Int J Infect Dis. 2021 Jul; 108:419-421. PMID: 34087489; PMCID: PMC8221824.
      Citations:    Fields:    Translation:HumansCellsPHPublic Health
    85. Bhamidipati D, Colina A, Hwang H, Wang H, Katz M, Fournier K, Serpas V, Thomas J, Sun R, Wolff RA, Raghav K, Overman MJ. Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy. ESMO Open. 2021 06; 6(3):100132. PMID: 33940348; PMCID: PMC8111574.
      Citations: 2     Translation:Humans
    86. Pedersen KS, Foster NR, Overman MJ, Boland PM, Kim SS, Arrambide KA, Jaszewski BL, Bekaii-Saab T, Graham RP, Welch J, Wilson RH, McWilliams RR. ZEBRA: A Multicenter Phase II Study of Pembrolizumab in Patients with Advanced Small-Bowel Adenocarcinoma. Clin Cancer Res. 2021 07 01; 27(13):3641-3648. PMID: 33883178.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    87. Raghav K, Hwang H, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR, J?come AA. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clin Cancer Res. 2021 06 15; 27(12):3414-3421. PMID: 33858857; PMCID: PMC8197749.
      Citations: 2     Fields:    Translation:Humans
    88. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5. PMID: 34250391; PMCID: PMC8232253.
      Citations: 5     Fields:    Translation:Humans
    89. Kanikarla Marie P, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, Foo WC, Maru DM, Chun YS, Futreal A, Kee B, Menter D, Solis L, Tzeng CW, Parseghian C, Raghav K, Morris V, Chang CC, Jenq R, Tam A, Bernatchez C, Kopetz S, Vauthey JN, Overman MJ. Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. Clin Cancer Res. 2021 06 01; 27(11):3039-3049. PMID: 33811152; PMCID: PMC8172528.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    90. Kadakia KT, Asaad M, Adlakha E, Overman MJ, Checka CM, Offodile AC. Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions. JCO Clin Cancer Inform. 2021 04; 5:421-425. PMID: 33830789.
      Citations: 3     Fields:    Translation:Humans
    91. Perri G, Prakash L, Wang H, Bhosale P, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay E, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021 04 01; 273(4):806-813. PMID: 31274655; PMCID: PMC7703852.
      Citations: 13     Fields:    Translation:Humans
    92. Mason MC, Tzeng CD, Tran Cao HS, Aloia TA, Newhook TE, Overman MJ, Kopetz SE, Vauthey JN, Chun YS. Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases. J Am Coll Surg. 2021 07; 233(1):82-89.e1. PMID: 33667566; PMCID: PMC8238806.
      Citations: 2     Fields:    Translation:Humans
    93. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 03 02; 19(3):329-359. PMID: 33724754.
      Citations: 98     Fields:    Translation:HumansCells
    94. Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist. 2021 04; 26(4):e650-e657. PMID: 33524217; PMCID: PMC8018327.
      Citations: 1     Fields:    Translation:Humans
    95. Ludford K, Foo WC, Thomas JV, Morris VK, Kopetz S, Chang GJ, Overman M, Cohen R, Svrcek M, Colle R, Parc Y, Andre T. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst. 2021 02 01; 113(2):208-211. PMID: 32294214; PMCID: PMC7850519.
      Citations: 10     Fields:    Translation:HumansCells
    96. Mehrvarz Sarshekeh A, Alshenaifi J, Roszik J, Manyam GC, Advani SM, Katkhuda R, Verma A, Lam M, Willis J, Shen JP, Morris J, Davis JS, Loree JM, Lee HM, Ajani JA, Maru DM, Overman MJ, Kopetz S. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670. PMID: 33414133; PMCID: PMC7956157.
      Citations: 7     Fields:    Translation:HumansCells
    97. Hui D, Puac V, Shelal Z, Liu D, Maddi R, Kaseb A, Javle M, Overman M, Yennurajalingam S, Gallagher C, Bruera E. Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial. J Pain Symptom Manage. 2021 08; 62(2):223-232.e1. PMID: 33388382.
      Citations:    Fields:    Translation:Humans
    98. Colina A, Hwang H, Wang H, Katz MHG, Sun R, Lee JE, Thomas J, Tzeng CW, Wolff RA, Raghav K, Overman MJ. Natural history and prognostic factors for localised small bowel adenocarcinoma. ESMO Open. 2020 11; 5(6):e000960. PMID: 33188051; PMCID: PMC7668374.
      Citations: 4     Translation:Humans
    99. Gulhati P, Yin J, Pederson L, Schmoll HJ, Hoff P, Douillard JY, Tournigand C, Tebbut N, Chibaudel B, Gramont A, Shi Q, Overman MJ, Hecht JR. Threshold Change in CEA as a Predictor of?Non-Progression to First-Line Systemic Therapy in Metastatic Colorectal Cancer Patients With Elevated CEA. J Natl Cancer Inst. 2020 11 01; 112(11):1127-1136. PMID: 32191317; PMCID: PMC7669230.
      Citations: 9     Fields:    Translation:Humans
    100. Morris JS, Luthra R, Liu Y, Duose DY, Lee W, Reddy NG, Windham J, Chen H, Tong Z, Zhang B, Wei W, Ganiraju M, Broom BM, Alvarez HA, Mejia A, Veeranki O, Routbort MJ, Morris VK, Overman MJ, Menter D, Katkhuda R, Wistuba II, Davis JS, Kopetz S, Maru DM. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting. Clin Cancer Res. 2021 01 01; 27(1):120-130. PMID: 33109741; PMCID: PMC8713413.
      Citations: 7     Fields:    Translation:HumansCells
    101. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer. 2021 06; 20(2):137-147.e1. PMID: 33229221.
      Citations: 4     Fields:    Translation:HumansCells
    102. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist. 2021 02; 26(2):107-114. PMID: 32960478; PMCID: PMC7873318.
      Citations: 3     Fields:    Translation:Humans
    103. Kamarinos NV, Dawson LA, Saltz LB, Crane CH, Overman MJ, Vauthey JN, Odisio BC, Denys A, Pereira PL, Sze DY, Vogl TJ, Meijerink MR, Kim HS, Solomon SB, Sofocleous CT, de Ba?re T, Helmberger T. Trials of locoregional therapies inspired by SABR-COMET. Lancet. 2020 10 03; 396(10256):956-957. PMID: 33010838.
      Citations: 2     Fields:    Translation:Humans
    104. Raghav K, Overman M, Poage GM, Soifer HS, Schnabel CA, Varadhachary GR. Defining a Distinct Immunotherapy Eligible Subset of Patients with Cancer of Unknown Primary Using Gene Expression Profiling with the 92-Gene Assay. Oncologist. 2020 11; 25(11):e1807-e1811. PMID: 32893931; PMCID: PMC7648339.
      Citations: 2     Fields:    Translation:Humans
    105. Hill A, Elakkad A, Kuban J, Sabir S, Odisio B, Huang SY, Mahvash A, Miller E, Kroll MH, Overman M, Tam AL, Gupta S, Sheth RA. Durability of partial splenic artery embolization on platelet counts for cancer patients with hypersplenism-related thrombocytopenia. Abdom Radiol (NY). 2020 09; 45(9):2886-2894. PMID: 32314004.
      Citations: 2     Fields:    Translation:Humans
    106. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2020 09 01; 155(9):832-839. PMID: 32667641; PMCID: PMC7364337.
      Citations: 29     Fields:    Translation:Humans
    107. Cheng LC, Chao YJ, Overman MJ, Wang C-, Phan NN, Chen YL, Wang TW, Hsu HP, Shan YS, Lai MD. Increased expression of secreted frizzled related protein 1 (SFRP1) predicts ampullary adenocarcinoma recurrence. Sci Rep. 2020 08 06; 10(1):13255. PMID: 32764696; PMCID: PMC7413269.
      Citations: 9     Fields:    Translation:HumansCells
    108. Raghav K, Shen JP, Guerra JL, Scally CP, Taggart MW, Foo WC, Matamoros A, Shaw KR, Fournier K, Overman MJ, Eng C, J?come AA. Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. Br J Cancer. 2020 10; 123(8):1262-1270. PMID: 32733093; PMCID: PMC7553941.
      Citations: 1     Fields:    Translation:Humans
    109. Vadhan-Raj S, O'Reilly EM, Overman MJ, Zhou X, Vijapurkar U, Kaul S, Wildgoose P, Khorana AA, McNamara MG, Venerito M, Riess H. Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med. 2020 09; 9(17):6196-6204. PMID: 32663379; PMCID: PMC7476843.
      Citations: 7     Fields:    Translation:Humans
    110. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Garrido-Laguna I, Grem JL, Gunn A, Hoffe S, Hubbard J, Hunt S, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gurski LA. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020. J Natl Compr Canc Netw. 2020 07; 18(7):806-815. PMID: 32634771.
      Citations: 67     Fields:    Translation:Humans
    111. Sheth RA, Murthy R, Hong DS, Patel S, Overman MJ, Diab A, Hwu P, Tam A. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Netw Open. 2020 07 01; 3(7):e207911. PMID: 32725245.
      Citations: 7     Fields:    Translation:HumansCells
    112. Ohinata A, Mahvash A, Overman MJ, Kee B, Fogelman D, Morris VK, Johnson B, Rothschild ND, Wolff RA, Eng C, J?come AA. Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clin Colorectal Cancer. 2020 12; 19(4):e189-e199. PMID: 32680816.
      Citations:    Fields:    Translation:Humans
    113. Rogers JE, Mizrahi JD, Xiao L, Mohindroo C, Shroff RT, Wolff R, Varadhachary GR, Javle MM, Overman M, Fogelman DR, Raghav KPS, Pant S, McAllister F. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Med. 2020 08; 9(15):5406-5415. PMID: 32519420; PMCID: PMC7402810.
      Citations: 2     Fields:    Translation:Humans
    114. Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C, J?come AA. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer. 2020 12; 19(4):248-255.e6. PMID: 32665092.
      Citations:    Fields:    Translation:Humans
    115. Perri G, Prakash L, Qiao W, Varadhachary GR, Wolff R, Fogelman D, Overman M, Pant S, Javle M, Koay EJ, Herman J, Kim M, Ikoma N, Tzeng CW, Lee JE, Katz MHG. Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma. Ann Surg. 2020 06; 271(6):996-1002. PMID: 31895709.
      Citations: 8     Fields:    Translation:Humans
    116. Overman MJ. Letting go of the physical exam: embracing telehealth solutions to oncology. J Cancer Metastasis Treat. 2020; 6. PMID: 34841086; PMCID: PMC8623945.
      Citations:    
    117. Unger JM, Hershman DL, Osarogiagbon RU, Gothwal A, Anand S, Dasari A, Overman M, Loree JM, Raghav K. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectr. 2020 Aug; 4(4):pkaa034. PMID: 32704619; PMCID: PMC7368466.
      Citations: 14     Fields:    
    118. Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol. 2020 07; 31(7):861-872. PMID: 32272210.
      Citations:    
    119. Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, Fu S. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080. PMID: 32080210; PMCID: PMC7033174.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    120. Thomas J, Leal A, Overman MJ. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clin Colorectal Cancer. 2020 06; 19(2):73-81. PMID: 32173280.
      Citations: 13     Fields:    Translation:HumansCells
    121. Overman M, Javle M, Davis RE, Vats P, Kumar-Sinha C, Xiao L, Mettu NB, Parra ER, Benson AB, Lopez CD, Munugalavadla V, Patel P, Tao L, Neelapu S, Maitra A. Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1). PMID: 32114502; PMCID: PMC7057435.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    122. Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology. 2020 Apr; 20(3):501-504. PMID: 31932214; PMCID: PMC7160008.
      Citations: 7     Fields:    Translation:Humans
    123. Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, Shroff RT, Varadhachary GR, Wolff RA, McAllister F, Futreal A, Fogelman DR. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer. Clin Cancer Res. 2020 03 15; 26(6):1385-1394. PMID: 31871297.
      Citations: 14     Fields:    Translation:Humans
    124. Goswami S, Walle T, Cornish AE, Basu S, Anandhan S, Fernandez I, Vence L, Blando J, Zhao H, Yadav SS, Ott M, Kong LY, Heimberger AB, de Groot J, Sepesi B, Overman M, Kopetz S, Allison JP, Pe'er D, Sharma P. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46. PMID: 31873309; PMCID: PMC7182038.
      Citations: 99     Fields:    Translation:HumansAnimalsCells
    125. Raghav K, Loree JM, Morris JS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Korphaisarn K, Kee B, Muranyi A, Singh S, Routbort M, Chen K, Shaw KRM, Katkhuda R, Shanmugam K, Maru D, Fakih M, Kopetz S. Validation of HER2 Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019 Dec; 3:1-13. PMID: 35100667.
      Citations:    Fields:    
    126. Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, Bahary N, Suga JM, Hatoum H, Abrams JS, Conley BA, Arteaga CL, Harris L, O'Dwyer PJ, Chen AP, Flaherty KT. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. J Clin Oncol. 2020 01 20; 38(3):214-222. PMID: 31765263; PMCID: PMC6968795.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    127. Franke AJ, Skelton WP, Starr JS, Parekh H, Lee JJ, Overman MJ, Allegra C, George TJ. Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. J Natl Cancer Inst. 2019 11 01; 111(11):1131-1141. PMID: 31322663; PMCID: PMC6855933.
      Citations: 48     Fields:    Translation:Humans
    128. Advani SM, Shi Q, Overman MJ, Loree JM, Lam M, Morris V, Shureiqi I, Kee B, Dasari A, Vilar E, Sarshekeh AM, Lin HK, Manuel S, Hamilton S, Raghav K, Maru D, Kopetz S, Wang XS. Patient-reported Symptom Outcomes and Microsatellite Instability in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2020 03; 19(1):48-56.e2. PMID: 32008976.
      Citations: 1     Fields:    Translation:HumansCells
    129. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer. 2019 Oct 17; 19(1):965. PMID: 31623602; PMCID: PMC6796453.
      Citations: 7     Fields:    Translation:Humans
    130. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol. 2019 Oct 01; 5(10):e191870. PMID: 31415071; PMCID: PMC6696743.
      Citations: 67     Fields:    
    131. Pedersen KS, Raghav K, Overman MJ. Small Bowel Adenocarcinoma: Etiology, Presentation, and Molecular Alterations. J Natl Compr Canc Netw. 2019 09 01; 17(9):1135-1141. PMID: 31487680.
      Citations: 13     Fields:    Translation:Humans
    132. Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen SA, Cooper HS, Deming DA, Garrido-Laguna I, Grem JL, Hoffe SE, Hubbard J, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen KS, Saltz LB, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Johnson-Chilla A, Gregory KM, Gurski LA. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 09 01; 17(9):1109-1133. PMID: 31487687; PMCID: PMC10191182.
      Citations: 32     Fields:    Translation:Humans
    133. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer. 2019 09; 121(6):505-510. PMID: 31406299; PMCID: PMC6738104.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    134. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol. 2019; 3. PMID: 32914034; PMCID: PMC7446507.
      Citations: 4     Fields:    
    135. Willis JA, Overman MJ, Vilar E. Mismatch Repair-Proficient Colorectal Cancer: Finding the Right TiME to Respond. Clin Cancer Res. 2019 09 01; 25(17):5185-5187. PMID: 31263028; PMCID: PMC6726523.
      Citations: 2     Fields:    Translation:HumansCells
    136. Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B. Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer. Oncologist. 2019 11; 24(11):1453-1461. PMID: 31147488; PMCID: PMC6853093.
      Citations: 23     Fields:    Translation:HumansCellsCTClinical Trials
    137. Lieu CH, Corcoran RB, Overman MJ. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:207-215. PMID: 31099678.
      Citations: 9     Fields:    Translation:Humans
    138. Overman MJ. Immunotherapy in colorectal cancer with mismatch repair deficiency. Clin Adv Hematol Oncol. 2019 May; 17(5):265-267. PMID: 31188802.
      Citations: 1     Fields:    Translation:HumansCells
    139. Bhamidipati D, Anand S, Gothwal A, Raghav K, Overman MJ, Overman MJ. On the underreporting of health-related quality of life and regulatory approval. Ann Oncol. 2019 04 01; 30(4):657-658. PMID: 30698646.
      Citations:    
    140. Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019 04 15; 35(4):559-572.e7. PMID: 30905761; PMCID: PMC6467776.
      Citations: 153     Fields:    Translation:HumansAnimalsCells
    141. Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM. Clinical and molecular characterization of early-onset colorectal cancer. Cancer. 2019 06 15; 125(12):2002-2010. PMID: 30854646; PMCID: PMC6583775.
      Citations: 59     Fields:    Translation:Humans
    142. Parseghian CM, Tam AL, Yao J, Ensor J, Ellis LM, Raghav K, Overman MJ. Assessment of Reported Trial Characteristics, Rate of Publication, and Inclusion of Mandatory Biopsies of Research Biopsies in Clinical Trials in Oncology. JAMA Oncol. 2019 03 01; 5(3):402-405. PMID: 30383128; PMCID: PMC6439840.
      Citations: 6     Fields:    Translation:Humans
    143. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2019 03 01; 30(3):495. PMID: 29982323; PMCID: PMC6442652.
      Citations: 1     Fields:    
    144. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S, Parseghian CM, Vilar E, Corcoran RB. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol. 2019 02 01; 30(2):243-249. PMID: 30462160; PMCID: PMC6657008.
      Citations:    
    145. Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S. Back to the Colorectal Cancer Consensus Molecular Subtype Future. Curr Gastroenterol Rep. 2019 Jan 30; 21(2):5. PMID: 30701321; PMCID: PMC6622456.
      Citations: 22     Fields:    Translation:HumansCells
    146. Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer. 2019 02; 120(3):340-345. PMID: 30636774; PMCID: PMC6353894.
      Citations: 14     Fields:    Translation:Humans
    147. Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma P. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697. PMID: 30635425; PMCID: PMC6358697.
      Citations: 115     Fields:    Translation:HumansCells
    148. Aldrich JD, Raghav KPS, Varadhachary GR, Wolff RA, Overman MJ. Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma. Oncologist. 2019 06; 24(6):e384-e386. PMID: 30598498; PMCID: PMC6656507.
      Citations: 2     Fields:    Translation:Humans
    149. Serpas VJ, Raghav KP, Halperin DM, Yao J, Overman MJ. Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology. BMC Med Res Methodol. 2018 12 12; 18(1):169. PMID: 30541475; PMCID: PMC6292048.
      Citations: 1     Fields:    Translation:Humans
    150. Ko H, Yan M, Gupta R, Kebbel K, Maiti A, Song J, Nates J, Overman MJ. Predictors of Survival in Patients with Advanced Gastrointestinal Malignancies Admitted to the Intensive Care Unit. Oncologist. 2019 04; 24(4):483-490. PMID: 30518614; PMCID: PMC6459253.
      Citations: 3     Fields:    Translation:Humans
    151. Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K. Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer. J Natl Cancer Inst. 2018 12 01; 110(12):1409-1417. PMID: 29718453; PMCID: PMC6292791.
      Citations: 28     Fields:    Translation:Humans
    152. Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ. DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway. Clin Cancer Res. 2019 01 15; 25(2):641-651. PMID: 30352910; PMCID: PMC6335167.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    153. Mizrahi JD, Overman MJ. Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury. Oncotarget. 2018 Oct 09; 9(79):34857-34858. PMID: 30405879; PMCID: PMC6201853.
      Citations: 2     Fields:    
    154. O'Keefe CM, Pisanic TR, Zec H, Overman MJ, Herman JG, Wang TH. Facile profiling of molecular heterogeneity by microfluidic digital melt. Sci Adv. 2018 09; 4(9):eaat6459. PMID: 30263958; PMCID: PMC6157960.
      Citations: 18     Fields:    Translation:HumansCells
    155. Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG. Bioactive lipid metabolism in platelet "first responder" and cancer biology. Cancer Metastasis Rev. 2018 09; 37(2-3):439-454. PMID: 30112590.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    156. Overman MJ, Ellis LM, Joffe S. Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. JAMA Oncol. 2018 08 01; 4(8):1041-1042. PMID: 29799989.
      Citations: 2     Fields:    Translation:Humans
    157. Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hobbs B, Loyer EM, Kopetz S, Hoff PM. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia. J Natl Cancer Inst. 2018 08 01; 110(8):888-894. PMID: 29346573.
      Citations: 9     Fields:    Translation:Humans
    158. Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S. Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics. Clin Colorectal Cancer. 2018 12; 17(4):e699-e709. PMID: 30205948; PMCID: PMC6588353.
      Citations: 21     Fields:    Translation:HumansCells
    159. Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291. PMID: 29668571; PMCID: PMC6028046.
      Citations: 3     Fields:    Translation:Humans
    160. Abdel-Wahab R, Varadhachary GR, Bhosale PR, Wang X, Fogelman DR, Shroff RT, Overman MJ, Wolff RA, Javle M. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71. PMID: 29843755; PMCID: PMC5975422.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    161. Overman MJ, Ernstoff MS, Morse MA. Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:239-247. PMID: 30231358.
      Citations: 34     Fields:    Translation:HumansCells
    162. Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG. Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy. Front Oncol. 2018; 8:107. PMID: 29732316; PMCID: PMC5919962.
      Citations: 12     
    163. Mehrvarz Sarshekeh A, Overman MJ, Kopetz S. Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 2018 08; 14(18):1869-1874. PMID: 29473436; PMCID: PMC6088272.
      Citations: 13     Fields:    Translation:HumansCells
    164. Amer AM, Zaid M, Chaudhury B, Elganainy D, Lee Y, Wilke CT, Cloyd J, Wang H, Maitra A, Wolff RA, Varadhachary G, Overman MJ, Lee JE, Fleming JB, Tzeng CW, Katz MH, Holliday EB, Krishnan S, Minsky BD, Herman JM, Taniguchi CM, Das P, Crane CH, Le O, Bhosale P, Tamm EP, Koay EJ. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709. PMID: 29370450; PMCID: PMC5891375.
      Citations: 15     Fields:    Translation:Humans
    165. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, Andr? T. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 03 10; 36(8):773-779. PMID: 29355075.
      Citations: 617     Fields:    Translation:HumansCells
    166. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018 01 01; 29(1):139-144. PMID: 29069279; PMCID: PMC5834085.
      Citations: 11     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    167. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ. Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater. Oncologist. 2018 03; 23(3):277-e26. PMID: 29259073; PMCID: PMC5905687.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    168. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clin Cancer Res. 2018 03 01; 24(5):1062-1072. PMID: 29180604; PMCID: PMC5844818.
      Citations: 80     Fields:    Translation:Humans
    169. Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):e103-e108. PMID: 29196178.
      Citations: 1     Fields:    Translation:Humans
    170. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. JAMA Surg. 2017 Nov 01; 152(11):1048-1056. PMID: 28700784; PMCID: PMC5710421.
      Citations: 26     Fields:    Translation:Humans
    171. Schrock AB, Devoe CE, McWilliams R, Sun J, Stephens PJ, Ross JS, Wilson R, Miller VA, Ali SM, Overman MJ, Aparicio T. Genomic Profiling of Small-Bowel Adenocarcinoma. JAMA Oncol. 2017 Nov 01; 3(11):1546-1553. PMID: 28617917; PMCID: PMC5710195.
      Citations: 71     Fields:    Translation:HumansCells
    172. Mazard T, Boonsirikamchai P, Overman MJ, Asran MA, Choi H, Herron D, Eng C, Maru DM, Ychou M, Vauthey JN, Loyer EM, Kopetz S. Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. Gut. 2018 06; 67(6):1095-1102. PMID: 29084828; PMCID: PMC10109500.
      Citations: 8     Fields:    Translation:Humans
    173. Passot G, Kim BJ, Glehen O, Mehran RJ, Kopetz SE, Goere D, Overman MJ, Pocard M, Conrad C, Aloia TA, Vauthey JN, Chun YS, BIG-RENAPE Working Group, Marchal F. Impact of RAS Mutations in Metastatic Colorectal Cancer After Potentially Curative Resection: Does Site of Metastases Matter? Ann Surg Oncol. 2018 Jan; 25(1):179-187. PMID: 29071660.
      Citations: 9     Fields:    Translation:Humans
    174. Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CW, Kim M, Fleming JB, Vauthey JN, Katz MH, Lee JE, Conrad C. Pathologic Response to Preoperative Therapy as a Novel Prognosticator for Ampullary and Duodenal Adenocarcinoma. Ann Surg Oncol. 2017 Dec; 24(13):3954-3963. PMID: 28980211; PMCID: PMC6039188.
      Citations: 1     Fields:    Translation:Humans
    175. Sakellariou-Thompson D, Creasy C, Bernard V, Zhao L, Kim YU, Hurd MW, Uraoka N, Parra ER, Kang Y, Bristow CA, Rodriguez-Canales J, Fleming JB, Varadhachary G, Javle M, Overman MJ, Alvarez HA, Heffernan TP, Zhang J, Hwu P, Maitra A, Haymaker C, Bernatchez C, Forget MA. 4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7263-7275. PMID: 28947567; PMCID: PMC6097625.
      Citations: 21     Fields:    Translation:HumansCells
    176. Clarke CN, Lee MS, Wei W, Manyam G, Jiang ZQ, Lu Y, Morris J, Broom B, Menter D, Vilar-Sanchez E, Raghav K, Eng C, Chang GJ, Simon I, Bernards R, Overman M, Mills GB, Maru D, Kopetz S. Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. Ann Surg Oncol. 2017 Dec; 24(13):4051-4058. PMID: 28936799; PMCID: PMC6063735.
      Citations: 14     Fields:    Translation:Humans
    177. Grotz TE, Royal RE, Mansfield PF, Overman MJ, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade. World J Gastrointest Oncol. 2017 Sep 15; 9(9):354-362. PMID: 28979717; PMCID: PMC5605335.
      Citations: 6     
    178. Pereira AAL, Morelli MP, Overman M, Kee B, Fogelman D, Vilar E, Shureiqi I, Raghav K, Eng C, Manuel S, Crosby S, Wolff RA, Banks K, Lanman R, Talasaz A, Kopetz S, Morris V. Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One. 2017; 12(8):e0183949. PMID: 28850629; PMCID: PMC5574560.
      Citations: 12     Fields:    Translation:Humans
    179. Sagebiel TL, Mohamed A, Matamoros A, Taggart MW, Doamekpor F, Raghav KP, Mann GN, Mansfield PF, Eng C, Royal RE, Foo WC, Ensor JE, Fournier KF, Overman MJ. Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. Ann Surg Oncol. 2017 Nov; 24(12):3667-3672. PMID: 28831698.
      Citations: 5     Fields:    Translation:Humans
    180. Parseghian CM, Raghav K, Wolff RA, Ensor J, Yao J, Ellis LM, Tam AL, Overman MJ. Underreporting of Research Biopsies from Clinical Trials in Oncology. Clin Cancer Res. 2017 Nov 01; 23(21):6450-6457. PMID: 28754815; PMCID: PMC5668146.
      Citations: 4     Fields:    Translation:Humans
    181. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, Andr? T. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 09; 18(9):1182-1191. PMID: 28734759; PMCID: PMC6207072.
      Citations: 831     Fields:    Translation:HumansCellsCTClinical Trials
    182. Grotz TE, Overman MJ, Eng C, Raghav KP, Royal RE, Mansfield PF, Mann GN, Robinson KA, Beaty KA, Rafeeq S, Matamoros A, Taggart MW, Fournier KF. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017 Sep; 24(9):2646-2654. PMID: 28695394.
      Citations: 8     Fields:    Translation:Humans
    183. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget. 2017 Jun 13; 8(24):39268-39279. PMID: 28424412; PMCID: PMC5503612.
      Citations: 32     Fields:    Translation:Humans
    184. Uemura M, Qiao W, Fournier K, Morris J, Mansfield P, Eng C, Royal RE, Wolff RA, Raghav K, Mann GN, Overman MJ. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. BMC Cancer. 2017 05 15; 17(1):331. PMID: 28506255; PMCID: PMC5433007.
      Citations: 4     Fields:    Translation:Humans
    185. Vauthey JN, Mizuno T, Overman MJ, Soubrane O. Can we navigate chemotherapy-induced hepatic injuries from pathology to bedside? J Hepatol. 2017 07; 67(1):10-11. PMID: 28476639.
      Citations: 1     Fields:    
    186. Katsiampoura A, Raghav K, Jiang ZQ, Menter DG, Varkaris A, Morelli MP, Manuel S, Wu J, Sorokin AV, Rizi BS, Bristow C, Tian F, Airhart S, Cheng M, Broom BM, Morris J, Overman MJ, Powis G, Kopetz S. Modeling of Patient-Derived Xenografts in Colorectal Cancer. Mol Cancer Ther. 2017 07; 16(7):1435-1442. PMID: 28468778; PMCID: PMC5562363.
      Citations: 21     Fields:    Translation:HumansAnimals
    187. Subbiah V, Khawaja MR, Hong DS, Amini B, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D, Piha-Paul S, Fu S, Tsimberidou AM, Naing A, Janku F, Karp DD, Overman M, Eng C, Kopetz S, Meric-Bernstam F, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8). PMID: 28422758; PMCID: PMC5396533.
      Citations: 13     Fields:    
    188. Jiang ZQ, Katsiampoura AD, Parseghian C, Loree JM, Overman MJ, Kopetz S, Thierry AR, Pastor B, Sanchez C, Messaoudi SE, Ychou M. Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer. Clin Cancer Res. 2017 Aug 15; 23(16):4578-4591. PMID: 28400427; PMCID: PMC5562356.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    189. Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H. High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol. 2017 04 01; 28(4):741-747. PMID: 28104621; PMCID: PMC5834026.
      Citations: 149     Fields:    Translation:HumansCells
    190. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Gallick GE, Kopetz S, Pastor B, Ychou M, Thierry AR. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4146-4154. PMID: 28280091; PMCID: PMC5540760.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    191. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345. PMID: 28267766; PMCID: PMC5340382.
      Citations: 40     Fields:    
    192. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. Ann Surg Oncol. 2017 Jul; 24(7):2031-2039. PMID: 28124275.
      Citations: 8     Fields:    Translation:Humans
    193. Fogelman DR, Morris J, Xiao L, Hassan M, Vadhan S, Overman M, Javle S, Shroff R, Varadhachary G, Wolff R, Vence L, Maitra A, Cleeland C, Wang XS. A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients. Support Care Cancer. 2017 06; 25(6):1809-1817. PMID: 28111717.
      Citations: 14     Fields:    Translation:Humans
    194. Tao R, Tsai CJ, Jensen G, Eng C, Kopetz S, Overman MJ, Skibber JM, Rodriguez-Bigas M, Chang GJ, You YN, Bednarski BK, Minsky BD, Delclos ME, Koay E, Krishnan S, Crane CH, Das P. Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. Radiother Oncol. 2017 01; 122(1):146-151. PMID: 28057329.
      Citations: 16     Fields:    Translation:Humans
    195. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, Qiao W, Wang H, Morris J, Wolff RA, Overman MJ. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: A single-center, open-label, phase 2 study. Cancer. 2017 May 15; 123(6):1011-1017. PMID: 27859010; PMCID: PMC5548379.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    196. Cloyd JM, Katz MH, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky BD, Lee JH, Bhutani MS, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PW, Evans DB, Lee JE. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. J Gastrointest Surg. 2017 01; 21(1):164-174. PMID: 27778257.
      Citations: 38     Fields:    Translation:Humans
    197. Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. Oncotarget. 2016 Oct 11; 7(41):67495-67506. PMID: 27542211; PMCID: PMC5341892.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    198. Hong DS, Morris VK, El Osta B, Sorokin AV, Janku F, Fu S, Overman MJ, Piha-Paul S, Subbiah V, Kee B, Tsimberidou AM, Fogelman D, Bellido J, Shureiqi I, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R, Meric-Bernstam F, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365. PMID: 27729313; PMCID: PMC5562357.
      Citations: 100     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    199. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim M, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Varadhachary G, Shroff R, Wolff R, Javle M, Overman MJ, Fogelman D, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. J Gastrointest Surg. 2016 12; 20(12):1975-1985. PMID: 27730398.
      Citations: 7     Fields:    Translation:Humans
    200. Fournier K, Rafeeq S, Taggart M, Kanaby P, Ning J, Chen HC, Overman M, Raghav K, Eng C, Mansfield P, Royal R. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. Ann Surg Oncol. 2017 Jan; 24(1):187-193. PMID: 27660258.
      Citations: 13     Fields:    Translation:Humans
    201. Passot G, Denbo JW, Yamashita S, Kopetz SE, Chun YS, Maru D, Overman MJ, Brudvik KW, Conrad C, Aloia TA, Vauthey JN. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery. 2017 02; 161(2):332-340. PMID: 27592215.
      Citations: 17     Fields:    Translation:Humans
    202. Raghav K, Morris V, Tang C, Morelli P, Amin HM, Chen K, Manyam GC, Broom B, Overman MJ, Shaw K, Meric-Bernstam F, Maru D, Menter D, Ellis LM, Eng C, Hong D, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631. PMID: 27421137; PMCID: PMC5342368.
      Citations: 23     Fields:    Translation:Humans
    203. Overman MJ, Soifer HS, Schueneman AJ, Ensor J, Adsay V, Saka B, Neishaboori N, Wolff RA, Wang H, Schnabel CA, Varadhachary G. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 2016 08 22; 16:668. PMID: 27549176; PMCID: PMC4994309.
      Citations: 4     Fields:    Translation:Humans
    204. Lee MS, McGuffey EJ, Morris JS, Manyam G, Baladandayuthapani V, Wei W, Morris VK, Overman MJ, Maru DM, Jiang ZQ, Hamilton SR, Kopetz S. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016 06 14; 114(12):1352-61. PMID: 27272216; PMCID: PMC4984478.
      Citations: 38     Fields:    Translation:HumansCells
    205. Cloyd JM, Crane CH, Koay EJ, Das P, Krishnan S, Prakash L, Snyder RA, Varadhachary GR, Wolff RA, Javle M, Shroff RT, Fogelman D, Overman M, Wang H, Maitra A, Lee JE, Fleming JB, Katz MH. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cancer. 2016 09 01; 122(17):2671-9. PMID: 27243381; PMCID: PMC4992463.
      Citations: 14     Fields:    Translation:Humans
    206. Janku F, Huang HJ, Claes B, Falchook GS, Fu S, Hong D, Ramzanali NM, Nitti G, Cabrilo G, Tsimberidou AM, Naing A, Piha-Paul SA, Wheler JJ, Karp DD, Holley VR, Zinner RG, Subbiah V, Luthra R, Kopetz S, Overman MJ, Kee BK, Patel S, Devogelaere B, Sablon E, Maertens G, Mills GB, Kurzrock R, Meric-Bernstam F. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404. PMID: 27207774.
      Citations: 43     Fields:    Translation:HumansCells
    207. Raghav K, Mhadgut H, McQuade JL, Lei X, Ross A, Matamoros A, Wang H, Overman MJ, Varadhachary GR. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes. PLoS One. 2016; 11(5):e0154985. PMID: 27171493; PMCID: PMC4865168.
      Citations: 7     Fields:    Translation:Humans
    208. Link JT, Overman MJ. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges. Cancer J. 2016 May-Jun; 22(3):190-5. PMID: 27341597.
      Citations: 10     Fields:    Translation:HumansCells
    209. Hoffmann MS, Overman MJ, Nates JL. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. J Community Support Oncol. 2016 Apr; 14(4):178-9. PMID: 27152518.
      Citations:    Fields:    
    210. Grotz TE, Mansfield PF, Royal RE, Mann GN, Rafeeq S, Beaty KA, Overman MJ, Fournier KF. Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Ann Surg Oncol. 2016 09; 23(9):2914-9. PMID: 27027310.
      Citations: 3     Fields:    Translation:Humans
    211. Passot G, Chun YS, Kopetz SE, Overman MJ, Conrad C, Aloia TA, Vauthey JN. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. Eur J Surg Oncol. 2016 Sep; 42(9):1378-84. PMID: 27358198; PMCID: PMC5002377.
      Citations: 3     Fields:    Translation:Humans
    212. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol. 2016 06; 27(6):1068-1074. PMID: 27045102; PMCID: PMC6276928.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    213. Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE, Australian Pancreatic Cancer Genome Initiative, Pilarsky C, Overman MJ, Jamieson NB, Van Buren G, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA, Gr?tzmann R. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Rep. 2016 Feb 02; 14(4):907-919. PMID: 26804919; PMCID: PMC4982376.
      Citations: 47     Fields:    Translation:HumansCells
    214. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Rashid A, Yao JC, Kopetz S, Dasari A, Hoff PM. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016 Jun; 15(2):e1-7. PMID: 26810202; PMCID: PMC4885752.
      Citations: 16     Fields:    Translation:Humans
    215. Chouhan J, Gupta R, Ensor J, Raghav K, Fogelman D, Wolff RA, Fisch M, Overman MJ. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Med. 2016 Feb; 5(2):239-47. PMID: 26714799; PMCID: PMC4735773.
      Citations: 15     Fields:    Translation:Humans
    216. Asare EA, Compton CC, Hanna NN, Kosinski LA, Washington MK, Kakar S, Weiser MR, Overman MJ. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer. 2016 Jan 15; 122(2):213-21. PMID: 26506400; PMCID: PMC4860278.
      Citations: 27     Fields:    Translation:Humans
    217. Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, Raghav K, Subbiah V, Hess K, Meric-Bernstam F, Hong DS, Overman MJ. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015 Oct 16; 15:713. PMID: 26474549; PMCID: PMC4609167.
      Citations: 20     Fields:    Translation:Humans
    218. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581. PMID: 26405159; PMCID: PMC4695208.
      Citations: 1     Fields:    
    219. Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ. From Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in Oncology. J Clin Oncol. 2015 Nov 01; 33(31):3583-90. PMID: 26304898; PMCID: PMC4979242.
      Citations: 18     Fields:    Translation:Humans
    220. Li D, Pise MN, Overman MJ, Liu C, Tang H, Vadhan-Raj S, Abbruzzese JL. ABO non-O type as a risk factor for thrombosis in patients with pancreatic cancer. Cancer Med. 2015 Nov; 4(11):1651-8. PMID: 26275671; PMCID: PMC4673991.
      Citations: 8     Fields:    Translation:Humans
    221. Dineen S, Lynch PM, Rodriguez-Bigas MA, Bannon S, Taggart M, Reeves C, Modaro C, Overman M, Chang GJ, Skibber JM, You YN. A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Netw. 2015 Jul; 13(7):865-72. PMID: 26150580.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    222. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2015 Aug; 33(4):977-84. PMID: 26062928.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    223. Taggart MW, Abraham SC, Overman MJ, Mansfield PF, Rashid A. Goblet cell carcinoid tumor, mixed goblet cell carcinoid-adenocarcinoma, and adenocarcinoma of the appendix: comparison of clinicopathologic features and prognosis. Arch Pathol Lab Med. 2015 Jun; 139(6):782-90. PMID: 26030247.
      Citations: 23     Fields:    Translation:HumansCells
    224. Xia M, Overman MJ, Rashid A, Chatterjee D, Wang H, Katz MH, Fleming JB, Lee JE, Varadhachary GR, Wolff RA, Wang H. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma. Hum Pathol. 2015 Sep; 46(9):1315-22. PMID: 26165226.
      Citations: 3     Fields:    Translation:Humans
    225. Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21. PMID: 25980577; PMCID: PMC4494976.
      Citations: 50     Fields:    Translation:Humans
    226. Schueneman A, Goggins M, Ensor J, Saka B, Neishaboori N, Lee S, Maitra A, Varadhachary G, Rezaee N, Wolfgang C, Adsay V, Wang H, Overman MJ. Validation of histomolecular classification utilizing histological subtype, MUC1, and CDX2 for prognostication of resected ampullary adenocarcinoma. Br J Cancer. 2015 Jun 30; 113(1):64-8. PMID: 25989273; PMCID: PMC4647538.
      Citations: 15     Fields:    Translation:Humans
    227. Chen ZY, Raghav K, Lieu CH, Jiang ZQ, Eng C, Vauthey JN, Chang GJ, Qiao W, Morris J, Hong D, Hoff P, Tran H, Menter DG, Heymach J, Overman M, Kopetz S, Hoff P. Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. Br J Cancer. 2015 Mar 17; 112(6):1088-97. PMID: 25688736; PMCID: PMC4366901.
      Citations: 66     Fields:    Translation:HumansCells
    228. Overman MJ, Eng C, Raghav K, Matamoros A, Taggart M, Foo WC, Fournier K. Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist. 2015 Mar; 20(3):e3-4. PMID: 25745054; PMCID: PMC4350806.
      Citations: 2     Fields:    Translation:Humans
    229. Dineen SP, Royal RE, Hughes MS, Sagebiel T, Bhosale P, Overman M, Matamoros A, Mansfield PF, Fournier KF. A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol. 2015 Oct; 22(11):3640-6. PMID: 25698402; PMCID: PMC4565864.
      Citations: 6     Fields:    Translation:Humans
    230. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol. 2015 Apr; 26(4):731-736. PMID: 25628445; PMCID: PMC4374387.
      Citations: 95     Fields:    Translation:HumansCells
    231. Choe JH, Overman MJ, Fournier KF, Royal RE, Ohinata A, Rafeeq S, Beaty K, Phillips JK, Wolff RA, Mansfield PF, Eng C. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Ann Surg Oncol. 2015 Aug; 22(8):2578-84. PMID: 25582740.
      Citations: 11     Fields:    Translation:Humans
    232. Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Vauthey JN, Vilar E, Maru D, Kopetz S, Pereira AA, Rego JF, Hoff PM. Association between KRAS mutation and lung metastasis in advanced colorectal cancer. Br J Cancer. 2015 Feb 03; 112(3):424-8. PMID: 25535726; PMCID: PMC4453646.
      Citations: 40     Fields:    Translation:Humans
    233. Satelli A, Mitra A, Brownlee Z, Xia X, Bellister S, Overman MJ, Kopetz S, Ellis LM, Meng QH, Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin Cancer Res. 2015 Feb 15; 21(4):899-906. PMID: 25516888; PMCID: PMC4334736.
      Citations: 113     Fields:    Translation:HumansCells
    234. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer. 2014 Sep 10; 14:660. PMID: 25208577; PMCID: PMC4167273.
      Citations: 8     Fields:    Translation:Humans
    235. Kee BK, Morris JS, Slack RS, Crocenzi T, Wong L, Esparaz B, Overman M, Glover K, Jones D, Wen S, Fisch MJ. A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan. Support Care Cancer. 2015 Mar; 23(3):661-70. PMID: 25160493.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    236. Morris VK, Lucas FAS, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E. Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol. 2014 Oct; 25(10):2008-2014. PMID: 25009008; PMCID: PMC4176451.
      Citations: 29     Fields:    Translation:Humans
    237. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71. PMID: 25069797; PMCID: PMC4266576.
      Citations: 48     Fields:    Translation:Humans
    238. Fogelman DR, Holmes H, Mohammed K, Katz MH, Prado CM, Lieffers J, Garg N, Varadhachary GR, Shroff R, Overman MJ, Garrett C, Wolff RA, Javle M. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer? J Cachexia Sarcopenia Muscle. 2014 Dec; 5(4):307-13. PMID: 24740741; PMCID: PMC4248412.
      Citations: 11     Fields:    
    239. Aburjania N, Truskinovsky AM, Overman MJ, Lou E. Ampulla of vater adenocarcinoma in a BRCA2 germline mutation carrier. J Gastrointest Cancer. 2014 Mar; 45(1):87-90. PMID: 23417715.
      Citations: 1     Fields:    Translation:Humans
    240. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman MJ. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol. 2014 May; 25(5):1032-8. PMID: 24585723; PMCID: PMC4072907.
      Citations: 97     Fields:    Translation:Humans
    241. Guo R, Overman M, Chatterjee D, Rashid A, Shroff S, Wang H, Katz MH, Fleming JB, Varadhachary GR, Abbruzzese JL, Wang H. Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma. Hum Pathol. 2014 May; 45(5):1015-23. PMID: 24746206.
      Citations: 7     Fields:    Translation:Humans
    242. Meyers C, Reuben JM, Wang X, Qiao W, Manzullo E, Alvarez RH, Morrow PK, Gonzalez-Angulo AM, Wang XS, Mendoza T, Liu W, Holmes H, Hwang J, Pisters K, Overman M, Cleeland C, Escalante CP. A randomized, double-blind, 2-period, placebo-controlled crossover trial of a sustained-release methylphenidate in the treatment of fatigue in cancer patients. Cancer J. 2014 Jan-Feb; 20(1):8-14. PMID: 24445757; PMCID: PMC4510946.
      Citations: 22     Fields:    Translation:Humans
    243. Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ. Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2014 May; 22(5):1223-31. PMID: 24362907; PMCID: PMC5924730.
      Citations: 41     Fields:    Translation:Humans
    244. Shroff S, Overman MJ, Rashid A, Shroff RT, Wang H, Chatterjee D, Katz MH, Lee JE, Wolff RA, Abbruzzese JL, Fleming JB, Wang H. The expression of PTEN is associated with improved prognosis in patients with ampullary adenocarcinoma after pancreaticoduodenectomy. Arch Pathol Lab Med. 2013 Nov; 137(11):1619-26. PMID: 24168499; PMCID: PMC4640926.
      Citations: 5     Fields:    Translation:Humans
    245. Raghav KP, Shetty AV, Kazmi SM, Zhang N, Morris J, Taggart M, Fournier K, Royal R, Mansfield P, Eng C, Wolff RA, Overman MJ. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist. 2013; 18(12):1270-7. PMID: 24149137; PMCID: PMC3868421.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    246. Zenali M, Overman MJ, Rashid A, Broaddus RB, Wang H, Katz MH, Fleming JB, Abbruzzese JL, Wang H. Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma. Hum Pathol. 2013 Dec; 44(12):2792-8. PMID: 24139211; PMCID: PMC4378233.
      Citations: 4     Fields:    Translation:Humans
    247. Lieu CH, Tran H, Jiang ZQ, Mao M, Overman MJ, Lin E, Eng C, Morris J, Ellis L, Heymach JV, Kopetz S. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. PLoS One. 2013; 8(10):e77117. PMID: 24143206; PMCID: PMC3797099.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    248. Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63. PMID: 24092809; PMCID: PMC4158732.
      Citations: 18     Fields:    Translation:HumansCells
    249. Taggart MW, Galbincea J, Mansfield PF, Fournier KF, Royal RE, Overman MJ, Rashid A, Abraham SC. High-level microsatellite instability in appendiceal carcinomas. Am J Surg Pathol. 2013 Aug; 37(8):1192-200. PMID: 23648460; PMCID: PMC4140656.
      Citations: 12     Fields:    Translation:HumansCells
    250. Raghav K, Overman MJ. Small bowel adenocarcinomas--existing evidence and evolving paradigms. Nat Rev Clin Oncol. 2013 Sep; 10(9):534-44. PMID: 23897080; PMCID: PMC6076441.
      Citations: 60     Fields:    Translation:Humans
    251. Overman MJ, Zhang J, Kopetz S, Davies M, Jiang ZQ, Zhi-Qin J, Stemke-Hale K, Pilarsky C, Hamilton S, Hwang R, Abbruzzese JL, Varadhachary G, Broom B, Wang H, R?mmele P, Gr?tzmann R. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144. PMID: 23776447; PMCID: PMC3679143.
      Citations: 19     Fields:    Translation:Humans
    252. Overman MJ, Fournier K, Hu CY, Eng C, Taggart M, Royal R, Mansfield P, Chang GJ. Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg. 2013 Jun; 257(6):1072-8. PMID: 23001080; PMCID: PMC3855996.
      Citations: 24     Fields:    Translation:Humans
    253. Jiang ZQ, Varadhachary G, Wang X, Kopetz S, Lee JE, Wang H, Shroff R, Katz M, Wolff RA, Fleming J, Overman MJ. A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy. Ann Oncol. 2013 Sep; 24(9):2349-53. PMID: 23704197; PMCID: PMC3841462.
      Citations: 12     Fields:    Translation:Humans
    254. Khalil MA, Qiao W, Carlson P, George B, Javle M, Overman M, Varadhachary G, Wolff RA, Abbruzzese JL, Fogelman DR. The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. Invest New Drugs. 2013 Oct; 31(5):1375-83. PMID: 23645398.
      Citations: 4     Fields:    Translation:Humans
    255. Overman MJ. Rare but real: management of small bowel adenocarcinoma. Am Soc Clin Oncol Educ Book. 2013; 189-93. PMID: 23714497.
      Citations: 9     Fields:    Translation:Humans
    256. Overman M, Wang H, Varadhachary GR. Adjuvant chemotherapy for resected periampullary adenocarcinoma. JAMA. 2012 Nov 14; 308(18):1855; author reply 1855-6. PMID: 23149995.
      Citations: 2     Fields:    Translation:Humans
    257. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, Abbruzzese JL, Tam AL. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol. 2013 Jan 01; 31(1):17-22. PMID: 23129736; PMCID: PMC5545102.
      Citations: 125     Fields:    Translation:Humans
    258. Bilen MA, Taggart MW, Fournier K, Ellis LM, Mansfield PF, Eng C, Royal RE, Overman MJ. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. Acta Oncol. 2013 Jun; 52(5):1044-6. PMID: 23020527.
      Citations: 1     Fields:    Translation:Humans
    259. Andreou A, Kopetz S, Maru DM, Chen SS, Zimmitti G, Brouquet A, Shindoh J, Curley SA, Garrett C, Overman MJ, Aloia TA, Vauthey JN. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012 Oct; 256(4):642-50. PMID: 22968062; PMCID: PMC3856177.
      Citations: 21     Fields:    Translation:Humans
    260. Shaw C, Bassett RL, Fox PS, Schmeler KM, Overman MJ, Wallace MJ, Gupta S, Tam A. Palliative venting gastrostomy in patients with malignant bowel obstruction and ascites. Ann Surg Oncol. 2013 Feb; 20(2):497-505. PMID: 22965572; PMCID: PMC4262403.
      Citations: 12     Fields:    Translation:Humans
    261. Machado K, Mak MP, Shah N, Takahashi TK, Costa FP, Overman MJ, Kopetz S, Hoff PM, Ferrarotto R. A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. Eur J Cancer. 2012 Apr; 48(6):820-6. PMID: 22330318.
      Citations: 5     Fields:    Translation:Humans
    262. Garrett CR, George B, Viswanathan C, Bhadkamkar NA, Wen S, Baladandayuthapani V, You YN, Kopetz ES, Overman MJ, Kee BK, Eng C. Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. Clin Colorectal Cancer. 2012 Sep; 11(3):191-4. PMID: 22280844.
      Citations: 7     Fields:    Translation:Humans
    263. Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012 May; 19(5):1439-45. PMID: 22187121; PMCID: PMC3342860.
      Citations: 41     Fields:    Translation:Humans
    264. Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin Cancer Res. 2011 Oct 01; 17(19):6130-9. PMID: 21953501; PMCID: PMC5562355.
      Citations: 112     Fields:    Translation:Cells
    265. Overman MJ, Epner DE. Lost in translation: a fisherman's tale. J Clin Oncol. 2011 Oct 01; 29(28):3832-3. PMID: 21768468.
      Citations: 2     Fields:    Translation:Humans
    266. Lieu CH, Lambert LA, Wolff RA, Eng C, Zhang N, Wen S, Rafeeq S, Taggart M, Fournier K, Royal R, Mansfield P, Overman MJ. Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Ann Oncol. 2012 Mar; 23(3):652-658. PMID: 21653683; PMCID: PMC3331734.
      Citations: 35     Fields:    Translation:Humans
    267. Tanaka M, Chang P, Li Y, Li D, Overman M, Maru DM, Sethi S, Phillips J, Bland GL, Abbruzzese JL, Eng C. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin Cancer Res. 2011 Jul 01; 17(13):4531-40. PMID: 21551253.
      Citations: 22     Fields:    Translation:HumansCells
    268. Raghav KP, Taggart MW, Fournier KF, Overman MJ. Is malignant dedifferentiation for mucinous appendiceal neoplasms a valid phenomenon or merely histopathologic ambiguity? J Am Coll Surg. 2011 May; 212(5):906; author reply 907. PMID: 21530846.
      Citations: 3     Fields:    Translation:Humans
    269. Watkins J, Slade JH, Phan A, Eng C, Weissferdt A, Overman MJ. Fatal diffuse alveolar damage associated with oxaliplatin administration. Clin Colorectal Cancer. 2011 Sep; 10(3):198-202. PMID: 21855043.
      Citations: 6     Fields:    Translation:Humans
    270. Pathak P, Maru D, Agarwal A, Overman M, Hoff PM, Kopetz S, Ferrarotto R. Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone. Clin Colorectal Cancer. 2011 Sep; 10(3):178-82. PMID: 21855039.
      Citations: 21     Fields:    Translation:Humans
    271. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer. 2011 Oct 01; 117(19):4484-92. PMID: 21446046; PMCID: PMC3128184.
      Citations: 15     Fields:    Translation:Humans
    272. Brouquet A, Abdalla EK, Kopetz S, Garrett CR, Overman MJ, Eng C, Andreou A, Loyer EM, Madoff DC, Curley SA, Vauthey JN. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011 Mar 10; 29(8):1083-90. PMID: 21263087; PMCID: PMC3068054.
      Citations: 119     Fields:    Translation:Humans
    273. Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2010 Dec 01; 116(23):5374-82. PMID: 20715162.
      Citations: 44     Fields:    Translation:Humans
    274. Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, Kopetz S, Garrett C, Curley SA, Abdalla EK. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010 Jun; 210(6):934-41. PMID: 20510802.
      Citations: 82     Fields:    Translation:Humans
    275. Overman MJ, Kopetz S, Lin E, Abbruzzese JL, Wolff RA. Is there a role for adjuvant therapy in resected adenocarcinoma of the small intestine. Acta Oncol. 2010 May; 49(4):474-9. PMID: 20397775.
      Citations: 27     Fields:    Translation:Humans
    276. Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, Eng C, Hoff PM, Vauthey JN, Wolff RA, Kopetz S. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010 May 20; 28(15):2549-55. PMID: 20406923.
      Citations: 69     Fields:    Translation:Humans
    277. Overman MJ, Kazmi SM, Jhamb J, Lin E, Yao JC, Abbruzzese JL, Ho L, Ajani J, Phan A. Weekly docetaxel, cisplatin, and 5-fluorouracil as initial therapy for patients with advanced gastric and esophageal cancer. Cancer. 2010 Mar 15; 116(6):1446-53. PMID: 20108336.
      Citations: 18     Fields:    Translation:Humans
    278. Shapiro JF, Chase JL, Wolff RA, Lambert LA, Mansfield PF, Overman MJ, Ohinata A, Liu J, Wang X, Eng C. Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. Cancer. 2010 Jan 15; 116(2):316-22. PMID: 19904805.
      Citations: 37     Fields:    Translation:Humans
    279. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010 Jan 20; 28(3):453-9. PMID: 20008624; PMCID: PMC2815707.
      Citations: 186     Fields:    Translation:HumansCTClinical Trials
    280. Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, Wang H. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010 Jan 05; 102(1):144-50. PMID: 19935793; PMCID: PMC2813754.
      Citations: 48     Fields:    Translation:HumansCells
    281. Slade JH, Alattar ML, Fogelman DR, Overman MJ, Agarwal A, Maru DM, Coulson RL, Charnsangavej C, Vauthey JN, Wolff RA, Kopetz S. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer. 2009 Oct; 8(4):225-30. PMID: 19822514.
      Citations: 34     Fields:    Translation:Humans
    282. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009 Aug 01; 27(22):3677-83. PMID: 19470929; PMCID: PMC2720081.
      Citations: 440     Fields:    Translation:Humans
    283. Overman MJ. Recent advances in the management of adenocarcinoma of the small intestine. Gastrointest Cancer Res. 2009 May; 3(3):90-6. PMID: 19626152; PMCID: PMC2713134.
      Citations: 26     
    284. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009 Jun 01; 27(16):2598-603. PMID: 19164203.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    285. Overman M, Kopetz S. Picking the right road for metastatic colorectal cancer patients. Oncology (Williston Park). 2008 Nov 30; 22(13):1482-3. PMID: 19227576.
      Citations:    Fields:    Translation:Humans
    286. Blazer DG, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20; 26(33):5344-51. PMID: 18936472.
      Citations: 175     Fields:    Translation:Humans
    287. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008 Oct 15; 113(8):2038-45. PMID: 18759326.
      Citations: 37     Fields:    Translation:Humans
    288. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct; 26(8):794-9. PMID: 18798063.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    289. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer. 2008 Sep; 7(5):338-42. PMID: 18794067.
      Citations:    Fields:    Translation:Humans
    290. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abbruzzese JL. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008 Oct; 26(5):445-54. PMID: 18528634.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    291. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. J Clin Oncol. 2008 Apr 20; 26(12):2000-5. PMID: 18421052.
      Citations: 2     Fields:    Translation:Humans
    292. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. Clin Colorectal Cancer. 2008 Jan; 7(1):55-9. PMID: 18279578.
      Citations: 4     Fields:    Translation:Humans
    293. Overman MJ, Feng L, Pro B, McLaughlin P, Hess M, Samaniego F, Younes A, Romaguera JE, Hagemeister FB, Kwak L, Cabanillas F, Rodriguez MA, Fayad LE. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma. Ann Oncol. 2008 Mar; 19(3):553-9. PMID: 18083690.
      Citations: 6     Fields:    Translation:Humans
    294. Overman MJ, Hoff PM. EGFR-targeted therapies in colorectal cancer. Dis Colon Rectum. 2007 Aug; 50(8):1259-70. PMID: 17566832.
      Citations: 15     Fields:    Translation:Humans
    295. Overman M, Brass E. Worsening of thrombotic thromboctyopenic purpura symptoms associated with desmopressin administration. Thromb Haemost. 2004 Oct; 92(4):886-7. PMID: 15499705.
      Citations: 2     Fields:    Translation:Humans
    296. David-Beabes GL, Overman MJ, Petrofski JA, Campbell PA, de Marzo AM, Nelson WG. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity. Int J Oncol. 2000 Dec; 17(6):1077-86. PMID: 11078791.
      Citations: 17     Fields:    Translation:HumansCells
    297. Shurin PA, Giebink GS, Wegman DL, Ambrosino D, Rholl J, Overman M, Bauer T, Siber GR. Prevention of pneumococcal otitis media in chinchillas with human bacterial polysaccharide immune globulin. J Clin Microbiol. 1988 Apr; 26(4):755-9. PMID: 3366870; PMCID: PMC266440.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    298. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix. Cancer. 122:213-221.
    299. BRAF Mutation testing in cell-free DNA from the plasma of patients with advanced cancers using a rapid, automated molecular diagnostics system. Molecular Cancer Therapeutics. 15:1397-1404.
    300. Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. Cell Reports. 14:907-919.
    301. A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. Annals of Surgical Oncology. 22:3640-3646.
    302. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy. European Journal of Surgical Oncology.
    303. Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?. Journal of Cachexia, Sarcopenia and Muscle. 5:307-313.
    304. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater. Cancer.
    305. High-Grade Neuroendocrine Colorectal Carcinomas. Clinical Colorectal Cancer.
    306. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Annals of Oncology. 27:1068-1074.
    307. Reply. British Journal of Cancer. 103:1306.
    308. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. British Journal of Cancer. 114:1352-1361.
    309. Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer. Oncotarget. 7:67495-67506.
    310. Erratum to "Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies" [Oncotarget., 6 (2015) 12809-12821]. Oncotarget. 6:24581.
    311. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    312. Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP). Annals of Surgical Oncology. 1-7.
    313. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs.
    314. Hyperfractionated accelerated reirradiation for rectal cancer. Radiotherapy and Oncology.
    315. MET amplification in metastatic colorectal cancer. Oncotarget. 7:54627-54631.
    316. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discovery. 6:1352-1365.
    317. Intrathoracic Chemoperfusion Decreases Recurrences in Patients with Full-Thickness Diaphragm Involvement with Mucinous Appendiceal Adenocarcinoma. Annals of Surgical Oncology. 1-6.
    318. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of Oncology. 26:731-736.
    319. Retrospective analysis of systemic chemotherapy and total parenteral nutrition for the treatment of malignant small bowel obstruction. Cancer Medicine. 5:239-247.
    320. Cancers of the Small Bowel. 441-451.
    321. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 6:12809-12821.
    322. Acute benzodiazepine toxicity exacerbated by concomitant oral olanzapine. Journal of Community and Supportive Oncology. 14:178-179.
    323. Small bowel malignant tumors. 247-265.
    324. Pathologic complete response in poorly differentiated adenocarcinomas of the appendix. Acta Oncologica. 52:1046-1048.
    325. Erratum. PLoS One. 8.
    326. Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. Journal of Gastrointestinal Surgery. 1-11.
    327. Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma. Journal of Gastrointestinal Surgery. 1-11.
    328. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma. BMC Cancer. 16.
    329. Cancer of unknown primary in adolescents and young adults. PLoS One. 11.
    330. Immunotherapy progress in mismatch repair-deficient colorectal cancer and future therapeutic challenges. Cancer Journal (United States). 22:190-195.
    OVERMAN's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (596)
    Explore
    _
    Co-Authors (214)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _